Please assess the completion status of the following clinical trial:

Trial Title: Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven classical HL~* First diagnosis, no previous treatment~* Age: 18-60 years~* Stage I, IIA with risk factors a-d, IIB with RF c-d:~  1. large mediastinal mass~ 2. extranodal lesions~ 3. elevated ESR~ 4. ≥ 3 nodal areas confirmed by central review.~Exclusion Criteria:~* Composite lymphoma or nodular lymphocyte- predominant Hodgkin lymphoma (NLPHL)~* History of other malignancy ≤ 5 years~* Prior chemotherapy or radiation therapy~* Concurrent disease precluding protocol treatment~* Pregnancy, lactation~* Non-compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): 4 Cycles of Nivolumab plus AVD followed by IF-RT (30 Gy)
- Arm B (Type: EXPERIMENTAL): 4 Cycles of Nivolumab, followed by 2 cycles of Nivolumab plus AVD, followed by 2 Cycles of AVD followed by IF-RT (30 Gy)

Based on this trial design, predict the completion outcome and termination type (if applicable).